Hans Schambye, Galecto CEO
Not two weeks after closing a Series D round, Galecto files for $100M IPO
Galecto Biotech is pivoting to the public market less than two weeks after completing a $64 million Series D round.
The Copenhagen-based company filed its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
